AC
SRPT icon

Ascend Capital’s Sarepta Therapeutics SRPT Stock Holding History

Ascend Capital’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		$9.06M Sell
56,071
-45,344
-45% -$6.2M 0.45% 72
2018
Q2 		$13.4M Buy
101,415
+37,496
+59% +$3.54M 0.63% 53
2018
Q1 		$4.74M Buy
+63,919
New +$4.26M 0.19% 121

Other funds holding SRPT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
FAM
Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Ascend Capital's SRPT Position: Q3 2018 in Review

Ascend Capital reduced its Sarepta Therapeutics (SRPT) stake by 45% in Q3 2018, selling an estimated $6.2M and leaving 56,071 shares worth $9.06M. The position accounts for 0.45% of the portfolio, ranked #72.

Ascend Capital first reported a position in SRPT in Q1 2018 and has held it in 3 quarters since. The position peaked at $13.4M in Q2 2018. 345 funds tracked by Wall St. Rank hold SRPT as of Q3 2018.

  • Ascend Capital held 56,071 shares of Sarepta Therapeutics worth $9.06M as of Q3 2018.
  • Ascend Capital sold 45,344 Sarepta Therapeutics shares in Q3 2018, an estimated $6.2M.
  • Sarepta Therapeutics made up 0.45% of Ascend Capital's portfolio in Q3 2018, its #72 holding.
  • Ascend Capital first reported a position in Sarepta Therapeutics in Q1 2018 and has held it in 3 quarters since.
  • Ascend Capital's Sarepta Therapeutics position peaked at $13.4M in Q2 2018.
  • 345 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q3 2018.

Based on Ascend Capital's 13F filing for Q3 2018, filed 13 Nov 2018.